Guangzhou Weiboxin Biotechnology Co., Ltd. is a provincial-level “Little Giant” high-tech enterprise specializing in the forward R&D, manufacturing, sales, and technical services of diagnostic reagents for infectious diseases. The company is also recognized as a “Contract-Honoring and Credit-Keeping Enterprise” by Guangdong Province and a provincial demonstration unit for intellectual property. Additionally, it serves as an industry–university–research collaboration base for Guangdong Food and Drug Vocational College and as an executive director unit of the Veterinary Diagnostic and Biological Products Committee of the Guangdong Society of Animal Husbandry and Veterinary Medicine. Furthermore, the company has been designated as an innovative, high-potential enterprise by multiple research institutions, including the Entrepreneurship College of Jinan University in Guangdong Province, and has been awarded the “Specialized, Refined, Distinctive, and Innovative” enterprise title at both municipal and provincial levels.

The company has been awarded the “Most Investment-Valuable Enterprise” prize and the title of “Annual African Swine Fever and Porcine Disease Testing Service Provider.” It has also obtained approval numbers for veterinary drug products from the Ministry of Agriculture and Rural Affairs, including: Veterinary Drug Approval No. 191438923 (African Swine Fever Virus Fluorescent PCR Detection Kit), Veterinary Drug Approval No. 191438213 (Porcine Reproductive and Respiratory Syndrome Virus ELISA Antibody Detection Kit), Veterinary Drug Approval No. 191438875 (Classical Swine Fever Virus Blocking ELISA Antibody Detection Kit), and Veterinary Drug Approval No. 191438851 (Porcine Circovirus Type 2 ELISA Antibody Detection Kit). In the 11th China Innovation and Entrepreneurship Competition, the company was honored with the Excellence Award in the Biopharmaceutical Industry Growth Category; in the Nanotechnology Industry Technology Competition of the Science and Technology Innovation and Entrepreneurship Contest, it won the Provincial Second Prize in the Growth Category; and in the National Finals of the Nanotechnology Industry Technology Innovation Special Competition of the China Innovation and Entrepreneurship Competition, it secured the National Third Prize in the Growth Category. Furthermore, the company has consecutively received the A-Level Tax Credit Certificate, the Four-Star Trademark and Brand Certification, and the Two-Integration Management System Assessment Certificate each year. It has also obtained ISO 9001 International Quality Management System Certification, ISO 14001 International Environmental Management System Certification, and GMP Certification from the Ministry of Agriculture. Since its establishment, the company has been granted a total of 24 patents, including 5 invention patents, 15 utility model patents, and 4 design patents, as well as more than ten trademarks.

The company boasts robust technical capabilities and a team of world-class professionals, including dozens of masters, doctors, and returnees who studied abroad, as well as numerous senior-level technical experts. Currently, the company’s primary focus is on the research and development of molecular diagnostic reagents. Its core R&D team has developed more than 600 products spanning molecular diagnostics and immunoassays, including public-health–oriented fluorescent PCR test kits, animal disease–control–oriented fluorescent PCR test kits, clinical and research–grade fluorescent quantitative PCR kits, and transgenic–identification test kits (ZL2006). The company has established a nationwide distribution network covering over ten major cities, such as Beijing, Shanghai, Hangzhou, Nanjing, Wuhan, Xi’an, Yunnan, Chongqing, Chengdu, Guizhou, Lanzhou, Zhengzhou, Qingdao, Inner Mongolia, and Xinjiang.

Today, our products are exported far and wide to markets across the globe, including the United Arab Emirates, Oman, Egypt, Pakistan, Paraguay, Poland, Colombia, Kazakhstan, Mongolia, Bangladesh, Myanmar, Mexico, Nigeria, Saudi Arabia, Spain, Armenia, India, Indonesia, Vietnam, Cambodia, and many others, delivering high-quality products and services to customers worldwide.

Looking ahead, Weiboxin will remain steadfast in its commitment to continuously enhance product quality and service standards. Leveraging a rapid and efficient research platform and abundant biomedical resources, we will conduct extensive and in-depth R&D and scientific research in the biomedical field, thereby contributing to human health and advancing life sciences. Quality is our lifeline; innovation is our soul. Upholding this guiding principle, we will relentlessly strive to become the premier supplier of rapid diagnostic reagents and instruments.